When the heart’s largest valve leaks, complications can arise. A progressive form of the condition tricuspid regurgitation is considered among the toughest heart valve conditions to treat. Laplace Interventional is developing a novel solution that does not require open-heart surgery, reducing the possibility of future complications in patients. The company’s prosthetic valve can be delivered through a minimally invasive procedure, with a goal of increased life expectancy and improved quality of life.
Doctors are already praising the technology as easy to use with the potential to improve the lives of millions worldwide.
FinSMES – Laplace Interventional Raises $22M in Series C Funding
MassDevice – Laplace Interventional Raises $22M for Tricuspid Valve Tech
Medical Design and Outsourcing – 7 Startups Grabbing the Medtech Spotlight in Minnesota
Medical Device Network – Laplace Completes First Human Procedure with TTVR System
Medical Device Network – Laplace Interventional Locks in $12.9M from Series B Financing
Medical Device Network – Laplace Raises Funding to Complete Study of Tricuspid Valve Technology
MinneInno – Laplace Interventional Closes on $12.9M in Series B Financing
CRT (Cardiovascular Research Technologies) – 2025 Cardiovascular Innovation Award Runner-up
We invest in early-stage startups all around the world, often helping overseas companies open their first American offices. Click below to tell us about your work.
